<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: incur additional losses", fill: "#d8bfd8"},
{source: "9: incur additional losses", target: "9: foreseeable future", fill: "#d8bfd8"},
{source: "9: foreseeable future", target: "9: could increase as", fill: "#d8bfd8"},
{source: "9: could increase as", target: "9: development efforts", fill: "#d8bfd8"},
{source: "9: incur additional losses", target: "11: become profitable", fill: "#0014a8"},
{source: "11: become profitable", target: "11: must successfully", fill: "#0014a8"},
{source: "11: must successfully", target: "11: drug product candidates", fill: "#0014a8"},
{source: "11: drug product candidates", target: "11: agreements with", fill: "#0014a8"},
{source: "11: agreements with", target: "11: candidates must", fill: "#0014a8"},
{source: "11: candidates must", target: "11: regulatory approval", fill: "#0014a8"},
{source: "11: become profitable", target: "12: successfully", fill: "#cf0"},
{source: "12: successfully", target: "12: manufacture", fill: "#cf0"},
{source: "12: manufacture", target: "12: candidates", fill: "#cf0"},
{source: "12: successfully", target: "14: numerous risks", fill: "#30d5c8"},
{source: "14: numerous risks", target: "14: uncertainties associated with", fill: "#30d5c8"},
{source: "14: uncertainties associated with", target: "14: product candidates", fill: "#30d5c8"},
{source: "14: product candidates", target: "14: commercialization", fill: "#30d5c8"},
{source: "14: commercialization", target: "14: future losses", fill: "#30d5c8"},
{source: "14: future losses", target: "14: become profitable", fill: "#30d5c8"},
{source: "14: numerous risks", target: "17: additional financing", fill: "#00a550"},
{source: "17: additional financing", target: "17: development", fill: "#00a550"},
{source: "17: development", target: "17: commercialization", fill: "#00a550"},
{source: "17: commercialization", target: "17: product candidates", fill: "#00a550"},
{source: "17: product candidates", target: "17: development programs", fill: "#00a550"},
{source: "17: additional financing", target: "21: monthly cash used by operations will continue", fill: "#ff0090"},
{source: "21: monthly cash used by operations will continue", target: "21: clinical programs", fill: "#ff0090"},
{source: "21: monthly cash used by operations will continue", target: "37: enter into successful", fill: "#ff033e"},
{source: "37: enter into successful", target: "37: collaborative", fill: "#ff033e"},
{source: "37: collaborative", target: "37: arrangements", fill: "#ff033e"},
{source: "37: arrangements", target: "37: pharmaceutical", fill: "#ff033e"},
{source: "37: pharmaceutical", target: "37: companies research", fill: "#ff033e"},
{source: "37: companies research", target: "37: institutions", fill: "#ff033e"},
{source: "37: institutions", target: "37: government", fill: "#ff033e"},
{source: "37: government", target: "37: universities", fill: "#ff033e"},
{source: "37: universities", target: "37: development", fill: "#ff033e"},
{source: "37: development", target: "37: development regulatory approval", fill: "#ff033e"},
{source: "37: development regulatory approval", target: "37: marketing domestic", fill: "#ff033e"},
{source: "37: marketing domestic", target: "37: international sales", fill: "#ff033e"},
{source: "37: international sales", target: "37: distribution", fill: "#ff033e"},
{source: "37: distribution", target: "37: product candidates", fill: "#ff033e"},
{source: "37: enter into successful", target: "52: successfully", fill: "#deb887"},
{source: "52: successfully", target: "52: clinical studies", fill: "#deb887"},
{source: "52: clinical studies", target: "52: regulatory", fill: "#deb887"},
{source: "52: regulatory", target: "52: approvals manufacture market", fill: "#deb887"},
{source: "52: approvals manufacture market", target: "52: commercialize", fill: "#deb887"},
{source: "52: commercialize", target: "52: approved drugs", fill: "#deb887"},
{source: "52: successfully", target: "START_HERE", fill: "#deb887"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Provide shelter</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BIOCRYST PHARMACEUTICALS INC                              ITEM 1A RISK FACTORS                 An <font color="blue">investment</font> in our <font color="blue">stock involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You     should consider <font color="blue">carefully</font> the following risks, along with all of the other     information included in our other <font color="blue">filings with</font> the Securities and Exchange     Commission, before deciding to buy our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and     <font color="blue">uncertainties</font> not currently known to us or that we currently deem to be     <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">prevent events</font> that have a negative effect from occurring, then our business     may suffer</td>
    </tr>
    <tr>
      <td>Negative events are likely to decrease our revenue, increase our     costs, make our financial results poorer and/or decrease our financial     strength, and may cause our stock price to decline</td>
    </tr>
    <tr>
      <td>In that case, you may     lose all or a part of your <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Business       We have incurred substantial <font color="blue">losses since</font> our inception in 1986, expect to     continue to <font color="blue">incur such losses</font>, and may never be profitable</td>
    </tr>
    <tr>
      <td>Since our inception in 1986, we have not <font color="blue">been profitable</font></td>
    </tr>
    <tr>
      <td>We     expect to <font color="blue">incur <font color="blue">additional</font> losses</font> for the <font color="blue">foreseeable future</font>, and our losses     <font color="blue">could increase as</font> our research and <font color="blue"><font color="blue">development</font> efforts</font> progress</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, our <font color="blue">accumulated deficit</font> was <font color="blue">approximately</font> dlra151dtta9 million</td>
    </tr>
    <tr>
      <td>To <font color="blue">become profitable</font>, we <font color="blue">must <font color="blue">successfully</font></font> develop <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font>,     enter  into  profitable  <font color="blue"><font color="blue">agreements</font> with</font> other parties and our product     <font color="blue"><font color="blue">candidates</font> must</font> receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We or these other parties must     then <font color="blue">successfully</font> <font color="blue">manufacture</font> and market our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>It could be     <font color="blue">several years</font>, if ever, before we receive <font color="blue">royalties from</font> any current or     <font color="blue">future license <font color="blue">agreements</font></font> or <font color="blue">revenues directly from product sales</font></td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">numerous risks</font> and <font color="blue">uncertainties</font> associated with     developing our product <font color="blue">candidates</font> and their potential for <font color="blue">commercialization</font>,     we are unable to predict the extent of any <font color="blue">future losses</font> or when we will     <font color="blue">become profitable</font>, if at all</td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we may     not be able to sustain or increase <font color="blue">profitability</font> on a quarterly or annual     basis</td>
    </tr>
    <tr>
      <td>If we are unable to achieve and sustain <font color="blue">profitability</font>, the market     value of our <font color="blue">common stock</font> will likely decline</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue"><font color="blue">additional</font> financing</font>, we may be unable to complete the     <font color="blue">development</font> and <font color="blue">commercialization</font> of our product <font color="blue">candidates</font> or continue our     research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>To date, we have financed our <font color="blue">operations</font> primarily from sale of     our <font color="blue">equity securities</font> and, to a lesser extent, revenues from <font color="blue">collaboration</font>s     and interest</td>
    </tr>
    <tr>
      <td>Our <font color="blue">initial projection</font> for 2006 is that our <font color="blue">average burn rate</font> for     2006  will be <font color="blue">approximately</font> dlra2dtta5 million per month</td>
    </tr>
    <tr>
      <td>We expect that our     monthly cash used by <font color="blue">operations</font> <font color="blue">will continue</font> to increase for the next     couple of years as our <font color="blue">clinical programs</font> are expanded</td>
    </tr>
    <tr>
      <td>We are planning to be     in a <font color="blue">Phase IIb </font><font color="blue">pivotal trial with</font> Fodosine™ in 2006 in T-cell leukemia and     are in the <font color="blue"><font color="blue">early stage</font>s</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> in several other <font color="blue"><font color="blue">indications</font> with</font>     Fodosine™</td>
    </tr>
    <tr>
      <td>As  these  trials  increase in size and <font color="blue">patient <font color="blue">enrollment</font></font>     increases, our <font color="blue">costs <font color="blue">will increase</font></font></td>
    </tr>
    <tr>
      <td>In addition, we expect our <font color="blue">neuraminidase</font>     inhibitor, peramivir, to be in <font color="blue"><font color="blue">clinical trial</font>s</font> in the <font color="blue">first quarter</font> of 2006     and our <font color="blue">hepatitis</font> C <font color="blue">drug candidate</font>, BCX-4678 to be in <font color="blue"><font color="blue">clinical trial</font>s</font> during     2006</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">additional</font> trials</font> and the related <font color="blue">manufacturing</font>, personnel     resources  and  testing required to support these <font color="blue">studies will consume</font>     <font color="blue"><font color="blue">significant</font> capital resources</font> and <font color="blue">will increase</font> our expenses and our net     loss</td>
    </tr>
    <tr>
      <td>This <font color="blue">monthly burn rate could vary <font color="blue">significant</font>ly depending on</font> many     factors, including our ability to <font color="blue">raise <font color="blue">additional</font> capital</font>, the <font color="blue">development</font>     progress of our <font color="blue">existing partnerships</font> for our drug <font color="blue">candidates</font>, the amount of     funding or assistance we receive <font color="blue">from <font color="blue"><font color="blue">government</font>al agencies</font></font> or other new     <font color="blue">partnerships with <font color="blue">third parties</font></font> for the <font color="blue">development</font> of our drug <font color="blue">candidates</font>     in general and for peramivir specifically, the progress and results of our     current and proposed <font color="blue"><font color="blue">clinical trial</font>s</font> for Fodosine™, peramivir and BCX-4678,     the progress made in the <font color="blue">manufacturing</font> of our products and the <font color="blue">progression</font>     of our other programs</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had dlra60dtta0 million in     cash, cash <font color="blue">equivalents</font> and securities</td>
    </tr>
    <tr>
      <td>We raised dlra30 million (<font color="blue">approximately</font>     dlra29dtta9 million, net of expenses) in <font color="blue">December </font>2005 through a sale of equity to     provide the <font color="blue">resources <font color="blue">necessary</font></font> to continue the <font color="blue">development</font> of our existing     programs, while prudently maintaining our <font color="blue">cash position</font></td>
    </tr>
    <tr>
      <td>In addition, we     established a <font color="blue"><font color="blue">collaborative</font> relationship with</font> <font color="blue">Roche in November </font>2005 and a     <font color="blue"><font color="blue">collaborative</font> relationship with</font> <font color="blue">Mundipharma in February </font>2006, which provided     <font color="blue">additional</font>  cash  in  2006,  net of third party license fees, totaling     <font color="blue">approximately</font>  dlra32 million</td>
    </tr>
    <tr>
      <td>Our long-term capital <font color="blue">requirements</font> and the     adequacy of our <font color="blue">available funds will depend upon</font> many factors, including:                                         19                                           •       the progress of our research, drug <font color="blue">discovery</font> and <font color="blue">development</font> programs;                                                 •                  changes in <font color="blue">existing <font color="blue">collaborative</font> <font color="blue">relationships</font></font>;                                                 •        our ability to establish <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">relationships</font> with       academic <font color="blue">institutions</font>, <font color="blue">bio<font color="blue">technology</font></font> or <font color="blue"><font color="blue">pharmaceutical</font> companies</font>,                 <font color="blue"><font color="blue">government</font>al agencies</font> or other <font color="blue">third parties</font>;                                                 •     the extent to which our <font color="blue"><font color="blue">collaborator</font>s</font>, including <font color="blue"><font color="blue">government</font>al agencies</font> will    share in the costs associated with the <font color="blue">development</font> of our programs or run                      the <font color="blue">development</font> programs themselves;                                                 •     our ability to negotiate favorable <font color="blue">development</font> and <font color="blue">marketing alliances</font> for                          our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font>;                                                 •              the magnitude of our research and <font color="blue">development</font> programs;                                                 •    the scope and results of <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue"><font color="blue">clinical trial</font>s</font> to identify     <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> and the costs of <font color="blue">manufacturing</font> <font color="blue">drug product</font> to                       support these studies and trials;                                                 •                      <font color="blue">competitive</font> and <font color="blue"><font color="blue">technological</font> advances</font>;                                                 •           the time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s;                                                 •       the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining and                            <font color="blue">enforcing patent</font> claims;                                                 •       our <font color="blue">dependence on others</font> for <font color="blue">development</font> and <font color="blue">commercialization</font> of our                            product <font color="blue">candidates</font>; and                                                 •     successful <font color="blue">commercialization</font> of our <font color="blue">products consistent with</font> our licensing                                   strategy</td>
    </tr>
    <tr>
      <td>We will be required to <font color="blue">raise <font color="blue">additional</font> capital</font> to complete the     <font color="blue">development</font>  and  <font color="blue">commercialization</font> of our current product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font> funding, whether through <font color="blue">additional</font> sales of securities or     <font color="blue">collaborative</font> or other <font color="blue">arrangements</font> with corporate partners, <font color="blue">government</font>al     agencies or from other sources, may not be available when needed or on terms     acceptable to us</td>
    </tr>
    <tr>
      <td>The issuance of preferred or <font color="blue">common stock</font> or convertible     securities, with terms and <font color="blue">prices <font color="blue">significant</font>ly</font> more favorable than those of     the currently outstanding <font color="blue">common stock</font>, could have the effect of diluting or     <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ing</font> the holdings or rights of our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">collaborative</font> <font color="blue">arrangements</font> may require us to <font color="blue">transfer certain</font>     material rights to <font color="blue">such corporate partners as described</font> in the following     risk factor related to <font color="blue">collaborative</font> <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient </font>funds may     require us to delay, scale-back or <font color="blue">eliminate certain</font> of our research and     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>If we fail to establish <font color="blue">collaborative</font> <font color="blue">relationships</font> to <font color="blue"><font color="blue">commercialize</font> certain</font>     of our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> or if any <font color="blue"><font color="blue">collaborator</font> terminates</font> or fails to     perform its <font color="blue">obligations</font> under <font color="blue"><font color="blue">agreements</font> with</font> us, the <font color="blue">commercialization</font> of     our product <font color="blue">candidates</font> could be delayed or terminated</td>
    </tr>
    <tr>
      <td>A key aspect of our business strategy is to <font color="blue"><font color="blue">enter into</font> successful</font>     <font color="blue">collaborative</font>  <font color="blue">arrangements</font>  with  <font color="blue">pharmaceutical</font>  companies, research     <font color="blue">institutions</font>,  the  United  States <font color="blue">government</font> and <font color="blue">universities</font> for the     preclinical  <font color="blue">development</font>,  clinical  <font color="blue">development</font>, <font color="blue"><font color="blue">regulatory</font> approval</font>,     marketing, domestic and <font color="blue">international sales</font> and <font color="blue">distribution</font> of our drug     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">general strategy</font> is to rely upon other parties for     all of these steps so that we can <font color="blue">focus exclusively on</font> the key areas of our     expertise</td>
    </tr>
    <tr>
      <td>For some <font color="blue">smaller niche markets</font>, we may perform these steps     ourselves and outsource those functions where we do not have the internal     expertise</td>
    </tr>
    <tr>
      <td>Currently, we have established <font color="blue">collaborative</font> <font color="blue">relationships</font> with     two <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, <font color="blue">Roche and Mundipharma </font>for <font color="blue">development</font> and     <font color="blue">commercialization</font>  of  BCX-4208  and Fodosine™, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>There is     currently work being both planned and performed by various <font color="blue">government</font>al     agencies for the <font color="blue">development</font> of one of our drug <font color="blue">candidates</font>, peramivir, for     the  <font color="blue">potential use</font> in <font color="blue">avian influenza</font></td>
    </tr>
    <tr>
      <td>Any contracts with <font color="blue">government</font>al     <font color="blue">agencies may</font> not be completed on terms favorable to us, or at all, and any     <font color="blue">revenues under such contracts may</font> not cover the <font color="blue">development</font> costs of our     programs</td>
    </tr>
    <tr>
      <td>The  process of establishing <font color="blue">collaborative</font> <font color="blue">relationships</font> is     <font color="blue">difficult</font>,  time-consuming and <font color="blue">involves <font color="blue">significant</font> uncertainty</font></td>
    </tr>
    <tr>
      <td><font color="blue">Heavy     </font>reliance upon <font color="blue">collaborative</font> <font color="blue">relationships</font> with these <font color="blue">third parties</font> for these     <font color="blue">critical functions presents several risks</font>, including:                                         20                                           •     our <font color="blue"><font color="blue">collaborator</font>s</font> may seek to <font color="blue">renegotiate</font> or terminate their <font color="blue">relationships</font>      <font color="blue">with us due</font> to unsatisfactory clinical results, a change in business                strategy, a change of control or other reasons;                                                 •              our contracts for <font color="blue">collaborative</font> <font color="blue">arrangements</font> may expire;                                                 •     our <font color="blue">partners may</font> choose to <font color="blue">pursue <font color="blue">alternative</font> <font color="blue">technologies</font></font>, including those                              of our <font color="blue">competitors</font>;                                                 •        we may have <font color="blue">disputes with</font> a partner that could lead to <font color="blue">litigation</font> or                                  <font color="blue">arbitration</font>;                                                 •     we do not have day to <font color="blue">day <font color="blue">control over</font></font> the <font color="blue">activities</font> of our <font color="blue"><font color="blue">collaborator</font>s</font>                 and have limited <font color="blue">control over</font> their <font color="blue">decisions</font>;                                                 •        our ability to <font color="blue">generate future event payments</font> and <font color="blue">royalties from</font> our    <font color="blue"><font color="blue">collaborator</font>s</font> depends upon our <font color="blue"><font color="blue">collaborator</font>s</font>’ <font color="blue">abilities</font> to establish the   safety and efficacy of our drug <font color="blue">candidates</font>, obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s and    achieve <font color="blue">market <font color="blue">acceptance</font></font> of products developed from our drug <font color="blue">candidates</font>;                                                 •       our <font color="blue"><font color="blue">collaborator</font>s</font> may not properly maintain or defend our <font color="blue">intellectual</font>     <font color="blue">property rights</font>, where applicable, or they <font color="blue">may utilize</font> our <font color="blue">proprietary</font>   information in such a way as to invite <font color="blue">litigation</font> that <font color="blue">could jeopardize</font> or  potentially invalidate our <font color="blue">proprietary</font> information or expose us to potential                                   <font color="blue">liability</font>;                                                 •       our <font color="blue">partners may</font> not <font color="blue">devote sufficient capital</font> or <font color="blue">resources towards</font> our                            product <font color="blue">candidates</font>; and                                                 •         our <font color="blue">partners may</font> not comply with applicable <font color="blue">government</font> <font color="blue">regulatory</font>                                 <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If any <font color="blue">collaborator</font> fails to fulfill its <font color="blue">responsibilities</font> in a     <font color="blue">timely manner</font>, or at all, our <font color="blue">commercialization</font> efforts related to that     <font color="blue"><font color="blue">collaboration</font> could</font> be delayed or terminated, or it may be <font color="blue">necessary</font> for us     to assume <font color="blue">responsibility</font> for <font color="blue">activities</font> that <font color="blue">would otherwise</font> have been the     <font color="blue">responsibility</font>  of our <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>If we are unable to establish and     maintain <font color="blue">collaborative</font> <font color="blue">relationships</font> on acceptable terms, we may have to     delay or discontinue further <font color="blue">development</font> of one or more of our product     <font color="blue">candidates</font>, undertake <font color="blue">commercialization</font> <font color="blue">activities</font> at our own expense or     find  <font color="blue"><font color="blue">alternative</font> sources</font> of funding</td>
    </tr>
    <tr>
      <td>Any delay in the <font color="blue">development</font> or     <font color="blue">commercialization</font> of our compounds would severely affect our business,     because if our compounds do not progress through the <font color="blue">development</font> process or     reach  the  market  in  a <font color="blue">timely manner</font>, or at all, we may not receive     <font color="blue">additional</font> future event payments and may never receive product or royalty     payments</td>
    </tr>
    <tr>
      <td>We have not <font color="blue"><font color="blue">commercialize</font>d</font> any products or <font color="blue">technologies</font> and our future     <font color="blue">revenue generation</font> is uncertain</td>
    </tr>
    <tr>
      <td>We have not yet <font color="blue"><font color="blue">commercialize</font>d</font> any products or <font color="blue">technologies</font>, and     we may never be able to do so</td>
    </tr>
    <tr>
      <td>Our revenue from <font color="blue">collaborative</font> <font color="blue">agreements</font> is     <font color="blue">dependent upon</font> the status of our preclinical and <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>If we     fail to advance these programs to the point of being able to <font color="blue">enter into</font>     <font color="blue">successful <font color="blue">collaboration</font>s</font>, we will not receive any <font color="blue">future milestone</font> or other     <font color="blue">collaborative</font> payments</td>
    </tr>
    <tr>
      <td>Any future revenue directly from product sales would <font color="blue">depend on</font> our     ability  to  <font color="blue">successfully</font> complete <font color="blue">clinical studies</font>, obtain <font color="blue">regulatory</font>     approvals, <font color="blue">manufacture</font>, market and <font color="blue">commercialize</font> any <font color="blue">approved drugs</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">development</font> <font color="blue">collaboration</font>s with other <font color="blue">parties fail</font>, the <font color="blue">development</font>     of our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> will be delayed or stopped</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely heavily upon</font> other parties for many <font color="blue">important stages</font> of     our drug <font color="blue">development</font> programs, including:                                           •      <font color="blue">discovery</font> of proteins that cause or enable biological reactions <font color="blue">necessary</font>     for the <font color="blue">progression</font> of the disease or disorder, called enzyme targets;                                                 •      licensing or design of <font color="blue">enzyme inhibitors</font> for <font color="blue">development</font> as <font color="blue">drug product</font>                                  <font color="blue">candidates</font>;                                                 •      execution of some <font color="blue">pre<font color="blue">clinical studies</font></font> and late-stage <font color="blue">development</font> for our                       compounds and product <font color="blue">candidates</font>;                                         21                                           •      <font color="blue">management</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font>, including <font color="blue">medical monitoring</font> and data                                  <font color="blue">management</font>;                                                 •      execution of <font color="blue">additional</font> toxicology studies that may be required to obtain                      approval for our product <font color="blue">candidates</font>;                                                 •    <font color="blue">manufacturing</font> the <font color="blue">starting materials</font> required to formulate our <font color="blue"><font color="blue">drug product</font>s</font>   and the <font color="blue"><font color="blue">drug product</font>s</font> to be used in both our <font color="blue"><font color="blue">clinical trial</font>s</font> and toxicology                                    studies;                                                 •                     <font color="blue">management</font> of our <font color="blue">regulatory</font> function; and                                                 •     <font color="blue">manufacturing</font>, sales, marketing and <font color="blue">distribution</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our failure to engage in <font color="blue">successful <font color="blue">collaboration</font>s</font> at any one of     these <font color="blue">stages would greatly impact</font> our business</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">license enzyme</font>     targets or inhibitors from academic <font color="blue">institutions</font> or from other <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">companies on</font> acceptable terms, our product <font color="blue"><font color="blue">development</font> efforts</font> would suffer</td>
    </tr>
    <tr>
      <td>Similarly, if the <font color="blue">contract research organizations</font> that conduct our initial     or late-stage <font color="blue"><font color="blue">clinical trial</font>s</font>, conduct our toxicology studies, <font color="blue">manufacture</font>     our <font color="blue">starting materials</font> and <font color="blue"><font color="blue">drug product</font>s</font> or manage our <font color="blue">regulatory</font> function     breached  their  <font color="blue">obligations</font>  to  us,  this would delay or prevent the     <font color="blue">development</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> of <font color="blue">both intravenous</font> and <font color="blue">intramuscular dosing</font> of  peramivir     for <font color="blue">avian flu</font> is subject to all disclosed drug <font color="blue">development</font> and potential     <font color="blue">commercialization</font>  risks and numerous <font color="blue">additional</font> risks</td>
    </tr>
    <tr>
      <td>Any potential     <font color="blue">revenue benefits</font> to us are <font color="blue">highly speculative</font></td>
    </tr>
    <tr>
      <td>We have reinitiated <font color="blue">development</font> of our influenza <font color="blue">neuraminidase</font>     inhibitor, peramivir</td>
    </tr>
    <tr>
      <td>Further <font color="blue">development</font> and potential <font color="blue">commercialization</font> of     peramivir is subject to all the risks and <font color="blue">uncertainties</font> disclosed in our     other <font color="blue">risk factors</font> relating to drug <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In     addition, potential <font color="blue">commercialization</font> of peramivir is subject to further     risks, including the following:                                           •    the <font color="blue">injectable version</font> of peramivir is at an <font color="blue">early stage</font> of <font color="blue">development</font>, has          not been tested in humans and may not be safe or <font color="blue">effective</font>;                                                 •     <font color="blue">necessary</font> <font color="blue">government</font> or other <font color="blue">third party funding</font> and <font color="blue">clinical testing</font> for   further <font color="blue">development</font> of <font color="blue">peramivir may</font> not be available timely, at all, or in                              <font color="blue">sufficient amounts</font>;                                                 •     the <font color="blue">avian flu</font> prevention or <font color="blue">treatment concerns may</font> not <font color="blue">materialize at</font> all,                             or in the near future;                                                 •    advances in flu vaccines could <font color="blue">substantially</font> replace potential demand for an                          <font color="blue">antiviral such as peramivir</font>;                                                 •     any substantial demand for <font color="blue">avian flu</font> <font color="blue">treatments</font> may occur before peramivir           can be <font color="blue">adequately</font> developed and tested in <font color="blue"><font color="blue">clinical trial</font>s</font>;                                                 •      numerous large and well-established <font color="blue">pharmaceutical</font> and  <font color="blue">biotech companies</font>      will be competing to meet the <font color="blue">market demand</font> for <font color="blue">avian flu</font> drugs and                                   vaccines;                                                 •     <font color="blue">regulatory</font> <font color="blue">authorities</font> may not make needed <font color="blue">accommodations</font> to <font color="blue">accelerate</font> the              <font color="blue">drug testing</font> and <font color="blue">approval process</font> for peramivir; and                                                 •     in the <font color="blue">next few years</font>, it is expected that a limited number of <font color="blue">government</font>al   <font color="blue">entities will</font> be the <font color="blue">primary potential customers</font> for peramivir</td>
    </tr>
    <tr>
      <td>If any or all of these and other <font color="blue">risk factors</font> occur, we will not     <font color="blue">attain <font color="blue">significant</font> revenues</font> or gross margins from peramivir and our stock     <font color="blue">price will</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>22       Because we have limited <font color="blue">manufacturing</font> experience, we <font color="blue">depend on</font> third-party     <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font> our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> and the materials     for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we cannot rely on third-party <font color="blue">manufacture</font>rs,     we will be required to incur <font color="blue">significant</font> costs and <font color="blue">potential delays</font> in     finding new third-party <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience and only a small scale     <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We currently rely upon third-party <font color="blue">manufacture</font>rs to     <font color="blue">manufacture</font> the materials required for our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> and most     of the preclinical and <font color="blue">clinical quantities</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">depend on</font> these third-party <font color="blue">manufacture</font>rs to perform their <font color="blue">obligations</font> in a     <font color="blue">timely manner</font> and in <font color="blue">accordance with</font> applicable <font color="blue">government</font>al <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">manufacture</font>rs may encounter <font color="blue">difficult</font>ies with meeting our     <font color="blue">requirements</font>, including <font color="blue">problems involving</font>:                                           •                          <font color="blue">inconsistent production yields</font>;                                                 •      <font color="blue">interruption</font> of the delivery of materials required for the <font color="blue">manufacturing</font>                                    process;                                                 •    scheduling of plant time with other vendors or <font color="blue">unexpected equipment failure</font>;                                                 •             <font color="blue">potential catastrophes</font> that <font color="blue">could strike</font> their <font color="blue">facilities</font>;                                                 •       <font color="blue">poor quality control</font> and assurance or inadequate <font color="blue">process controls</font>; and                                                 •     lack of <font color="blue">compliance with <font color="blue">regulations</font></font> and <font color="blue">specifications set forth by</font> the <font color="blue">FDA                     </font>or other foreign <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>These contract <font color="blue">manufacture</font>rs may not be able to <font color="blue">manufacture</font> the     materials required or our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> at a cost or in quantities     <font color="blue">necessary</font> to make <font color="blue">them <font color="blue">commercially</font> viable</font></td>
    </tr>
    <tr>
      <td>We also have no <font color="blue">control over</font>     whether third-party <font color="blue">manufacture</font>rs breach their <font color="blue"><font color="blue">agreements</font> with</font> us or whether     they <font color="blue">may terminate</font> or decline to renew <font color="blue"><font color="blue">agreements</font> with</font> us</td>
    </tr>
    <tr>
      <td>To date, our     third party <font color="blue">manufacture</font>rs have met our <font color="blue">manufacturing</font> <font color="blue">requirements</font>, but they     may not continue to do so</td>
    </tr>
    <tr>
      <td>Furthermore, changes in the <font color="blue">manufacturing</font> process     or  procedure,  including  a  change in the location where the drug is     <font color="blue">manufacture</font>d or a change of a third-party <font color="blue">manufacture</font>r, may require prior     review and approval in <font color="blue">accordance with</font> the FDA’s current Good Manufacturing     Practices, or cGMPs, and comparable foreign <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">review may</font> be     costly  and  time-consuming and <font color="blue">could delay</font> or prevent the launch of a     product</td>
    </tr>
    <tr>
      <td>The FDA or similar foreign <font color="blue">regulatory</font> agencies at any time may also     implement new standards, or change their <font color="blue">interpretation</font> and <font color="blue">enforcement</font> of     existing standards for <font color="blue">manufacture</font>, packaging or testing of products</td>
    </tr>
    <tr>
      <td>If we     or  our contract <font color="blue">manufacture</font>rs are unable to comply, we or they may be     subject to <font color="blue">regulatory</font> action, civil actions or penalties</td>
    </tr>
    <tr>
      <td>If  we  are  unable to <font color="blue">enter into</font> <font color="blue"><font color="blue">agreements</font> with</font> <font color="blue">additional</font>     <font color="blue">manufacture</font>rs  on  <font color="blue">commercially</font>  <font color="blue">reasonable terms</font>, or if there is poor     <font color="blue">manufacturing</font> performance on the part of our third party <font color="blue">manufacture</font>rs, we     may  not  be  able  to complete <font color="blue">development</font> of, or market, our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our  raw  materials,  <font color="blue">drug substances</font>, and <font color="blue"><font color="blue">drug product</font>s</font> are     <font color="blue">manufacture</font>d by a limited group of suppliers and some at a <font color="blue">single <font color="blue">facility</font></font></td>
    </tr>
    <tr>
      <td>If any of these suppliers were unable to produce these items, this could     <font color="blue"><font color="blue">significant</font>ly impact</font> our supply of drugs for further pre<font color="blue">clinical testing</font> and     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We may be unable to establish sales, marketing and <font color="blue">distribution</font> <font color="blue">cap<font color="blue">abilities</font></font>     <font color="blue">necessary</font>  to  <font color="blue">successfully</font> <font color="blue">commercialize</font> products we may <font color="blue">successfully</font>     develop</td>
    </tr>
    <tr>
      <td>We  currently  have <font color="blue">no marketing capability</font> and no direct or     third-party sales or <font color="blue">distribution</font> <font color="blue">cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">successfully</font> develop a     <font color="blue">drug <font color="blue">product candidate</font></font> and decide to <font color="blue">commercialize</font> it <font color="blue">ourselves rather than</font>     relying on <font color="blue">third parties</font>, as we are considering doing in the <font color="blue"><font color="blue">United States </font>    </font>for  Fodosine™,  we  may  be  unable to establish marketing, sales and     <font color="blue">distribution</font>  <font color="blue">cap<font color="blue">abilities</font></font>  <font color="blue">necessary</font> to <font color="blue">commercialize</font> and <font color="blue">gain market</font>     <font color="blue">acceptance</font> for that product</td>
    </tr>
    <tr>
      <td>If the <font color="blue"><font color="blue">clinical trial</font>s</font> of our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> fail, our product     <font color="blue">candidates</font> will not be marketed, <font color="blue">which would</font> result in a complete absence of     product related revenue</td>
    </tr>
    <tr>
      <td>23                 To receive the <font color="blue"><font color="blue">regulatory</font> approval</font>s <font color="blue">necessary</font> for the sale of our     product <font color="blue">candidates</font>, we or our licensees must <font color="blue">demonstrate</font> through preclinical     studies  and  clinical  trials that <font color="blue">each <font color="blue">product candidate</font></font> is safe and     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If  we  or  other  third party <font color="blue"><font color="blue">collaborator</font>s</font> are unable to     <font color="blue">demonstrate</font> that our product <font color="blue">candidates</font> are safe and <font color="blue">effective</font>, our product     <font color="blue">candidates</font> will not receive <font color="blue"><font color="blue">regulatory</font> approval</font> and will not be marketed,     <font color="blue">which would</font> result in a complete absence of product related revenue</td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">clinical trial</font> process</font> is complex and uncertain</td>
    </tr>
    <tr>
      <td>Because of the cost and     duration of <font color="blue"><font color="blue">clinical trial</font>s</font>, we may decide to discontinue <font color="blue">development</font> of     product <font color="blue">candidates</font> that are <font color="blue">either unlikely</font> to show good results in the     trials or unlikely to <font color="blue">help advance</font> a product to the point of a <font color="blue">meaningful</font>     <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>Positive results from <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue">early clinical</font>     trials do not ensure positive results in <font color="blue"><font color="blue">clinical trial</font>s</font> designed to permit     <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font>, called pivotal <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We may     <font color="blue">suffer <font color="blue">significant</font> setbacks</font> in pivotal <font color="blue"><font color="blue">clinical trial</font>s</font>, even after earlier     <font color="blue"><font color="blue">clinical trial</font>s</font> show promising results</td>
    </tr>
    <tr>
      <td>Any of our product <font color="blue">candidates</font> may     produce undesirable side effects in humans</td>
    </tr>
    <tr>
      <td>These side <font color="blue">effects could</font> cause     us or <font color="blue">regulatory</font> <font color="blue">authorities</font> to interrupt, delay or halt <font color="blue"><font color="blue">clinical trial</font>s</font> of     a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>These side <font color="blue">effects could</font> also result in the FDA or     foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> refusing to approve the <font color="blue">product candidate</font> for     any targeted <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>We, our licensees, the FDA or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font> may suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at any time if we or     they believe the trial <font color="blue">participants</font> face unacceptable health risks</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical     </font><font color="blue">trials may fail</font> to <font color="blue">demonstrate</font> that our product <font color="blue">candidates</font> are safe or     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">negotiating</font> a <font color="blue">special protocol assessment</font>, or SPA, of the     clinical  trial  protocol for the proposed <font color="blue">Phase IIb </font><font color="blue">clinical trial</font> of     Fodosine™ in T-cell leukemia</td>
    </tr>
    <tr>
      <td>An SPA is an <font color="blue">agreement between</font> an applicant     and the FDA on the design and the size of <font color="blue"><font color="blue">clinical trial</font>s</font> that is intended     to form the basis of a New Drug Application (“NDA”)</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> an     SPA, an applicant may decide, or the FDA may require the applicant, to     modify the proposed protocol by, for example, changing the <font color="blue">proposed primary</font>     endpoint, the size of the study or otherwise, which may result in a delay in     the <font color="blue">initiation</font> or <font color="blue">completion</font> of the <font color="blue"><font color="blue">clinical trial</font>s</font> that are the subject of     the SPA These changes could arise from a change in the standard of care for     the <font color="blue">proposed indication</font> or other aspects of the protocol for the proposed     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>and an <font color="blue">applicant reach</font> an <font color="blue">agreement on</font> an SPA,     the SPA cannot be changed after the <font color="blue">clinical trial</font> begins, except in limited     <font color="blue">circumstances such as</font> a change in the science or <font color="blue">clinical knowledge about</font>     the <font color="blue">conditions</font> being studied</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> change to the protocols for a     <font color="blue">clinical trial</font> subject to an SPA would require prior FDA approval, which     <font color="blue">could delay</font> <font color="blue">implementation</font> of such a change and <font color="blue">continuation</font> and <font color="blue">completion</font>     of the related <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>We or our <font color="blue"><font color="blue">collaborator</font>s</font>     incur substantial expense for, and devote <font color="blue">significant</font> time to, preclinical     testing and <font color="blue"><font color="blue">clinical trial</font>s</font>, yet cannot be certain that the tests and trials     will ever result in the <font color="blue">commercial sale</font> of a product</td>
    </tr>
    <tr>
      <td>For example, clinical     trials require <font color="blue">adequate supplies</font> of drug and sufficient <font color="blue">patient <font color="blue">enrollment</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Delays  </font>in <font color="blue">patient <font color="blue">enrollment</font></font> can result in increased costs and longer     <font color="blue">development</font>  times</td>
    </tr>
    <tr>
      <td>Even if we or our licensees <font color="blue">successfully</font> complete     <font color="blue"><font color="blue">clinical trial</font>s</font> for our product <font color="blue">candidates</font>, we or our <font color="blue">licensees might</font> not     file the required <font color="blue">regulatory</font> submissions in a <font color="blue">timely manner</font> and may not     receive <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>If we or our licensees do not obtain and maintain <font color="blue">government</font>al approvals for     our products under <font color="blue">development</font>, we or our <font color="blue">partners will</font> not be able to sell     these  potential products, <font color="blue">which would</font> <font color="blue">significant</font>ly harm our business     because we will receive no revenue</td>
    </tr>
    <tr>
      <td>We  or  our licensees must obtain <font color="blue"><font color="blue">regulatory</font> approval</font> before     marketing or selling our future <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>If we or our licensees are     unable to receive <font color="blue"><font color="blue">regulatory</font> approval</font> and do not market or sell our future     <font color="blue"><font color="blue">drug product</font>s</font>, we will never receive any <font color="blue">revenue from such product sales</font></td>
    </tr>
    <tr>
      <td>In     the United States, we or our <font color="blue">partners must</font> obtain FDA approval for <font color="blue">each drug</font>     that we intend to <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">approval process</font> is typically     lengthy and expensive, and approval is <font color="blue">never certain</font></td>
    </tr>
    <tr>
      <td>Products <font color="blue">distributed</font>     abroad are also subject to foreign <font color="blue">government</font> regulation</td>
    </tr>
    <tr>
      <td>The FDA or foreign     <font color="blue">regulatory</font> agencies have not approved any of our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If     we or our <font color="blue">licensees fail</font> to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> we will be unable to     market and sell our future <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>We have several <font color="blue"><font color="blue">drug product</font>s</font> in     <font color="blue">various stages</font> of preclinical and clinical <font color="blue">development</font>; however, we are     unable  to  determine  when,  if  ever,  any of these <font color="blue">products will</font> be     <font color="blue">commercially</font>  available</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of  the  risks and <font color="blue">uncertainties</font> in     bio<font color="blue">pharmaceutical</font>  <font color="blue">development</font>,  our  product  <font color="blue">candidates</font> could take a     <font color="blue">significant</font>ly longer time to gain <font color="blue"><font color="blue">regulatory</font> approval</font> than we expect or may     never gain approval</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>delays <font color="blue"><font color="blue">regulatory</font> approval</font> of our product     <font color="blue">candidates</font>,  our <font color="blue">management</font>’s credibility, our company’s value and our     operating results may suffer</td>
    </tr>
    <tr>
      <td>Even if the FDA or foreign <font color="blue">regulatory</font> agencies     approve a <font color="blue">product candidate</font>, the approval may limit the indicated uses for a     <font color="blue">product candidate</font> and/or may require post-marketing studies</td>
    </tr>
    <tr>
      <td>24                 The FDA regulates, among other things, the record keeping and     storage  of  data  pertaining to potential <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently <font color="blue">store most</font></font> of our <font color="blue">preclinical research data at</font> our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we do <font color="blue">store duplicate copies</font> of most of our <font color="blue">clinical data offsite</font>, we could     <font color="blue">lose important preclinical data</font> if our <font color="blue">facility</font> incurs damage</td>
    </tr>
    <tr>
      <td>If we get     approval to market our potential products, whether in the <font color="blue">United States </font>or     <font color="blue">internationally</font>, we <font color="blue">will continue</font> to be subject to extensive <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font> are <font color="blue">wide ranging</font> and govern, among other     things:                                           •                   <font color="blue">adverse drug</font> experience reporting <font color="blue">regulations</font>;                                                 •                                 product promotion;                                                 •     product <font color="blue">manufacturing</font>, including good <font color="blue">manufacturing</font> practice <font color="blue">requirements</font>;                                      and                                                 •                         product changes or <font color="blue">modifications</font></td>
    </tr>
    <tr>
      <td>Our  failure  to  comply  <font color="blue">with existing</font> or future <font color="blue">regulatory</font>     <font color="blue">requirements</font>, or our loss of, or changes to, <font color="blue">previously</font> obtained approvals,     could have a material adverse effect on our business because we will not     receive product or <font color="blue">royalty revenues</font> if we or our licensees do not receive     approval of our products for marketing</td>
    </tr>
    <tr>
      <td>The FDA inspected us in November 1995 and issued us a List of     Inspectional Observations, <font color="blue">Form FDA </font>483, which cited our failure to follow     good <font color="blue">clinical practices</font></td>
    </tr>
    <tr>
      <td>The focus     was on the two 1995 <font color="blue">Phase II </font>dose-ranging studies of topical BCX-34 for the     treatment of CTCL and psoriasis</td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">investigation</font>, the FDA     issued us a <font color="blue">Form FDA </font>483, which cited our failure to follow good clinical     practices</td>
    </tr>
    <tr>
      <td>We are no longer developing BCX-34; however, as a consequence of     these  two <font color="blue">investigation</font>s, our ongoing and future <font color="blue">clinical studies</font> may     receive increased scrutiny, which may delay the <font color="blue">regulatory</font> review process</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> do not achieve broad <font color="blue">market <font color="blue">acceptance</font></font>, our     business may never <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> may not gain the <font color="blue">market <font color="blue">acceptance</font></font>     required for us to be <font color="blue">profitable even</font> if they <font color="blue">successfully</font> complete initial     and  final <font color="blue"><font color="blue">clinical trial</font>s</font> and receive approval for sale by the FDA or     foreign <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market <font color="blue">acceptance</font></font> of any product     <font color="blue">candidates</font>  that we or our partners develop will <font color="blue">depend on</font> a number of     factors, including:                                           •                   our <font color="blue">clinical evidence</font> of safety and efficacy;                                                 •     cost-<font color="blue">effective</font>ness, convenience and ease of use of our product <font color="blue">candidates</font>;                                                 •        their safety, <font color="blue">availability</font> and <font color="blue">effective</font>ness relative to <font color="blue">alternative</font>                                  <font color="blue">treatments</font>;                                                 •             the actual and potential side effects or other reactions;                                                 •          <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and third-party payers; and                                                 •       the <font color="blue">effective</font>ness of marketing and <font color="blue">distribution</font> support for our product                                  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, payers or the <font color="blue">medical community</font> in general     may not accept or use our product <font color="blue">candidates</font> even after the FDA or foreign     <font color="blue">regulatory</font> agencies approve the drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If our product <font color="blue">candidates</font>     do  not achieve <font color="blue">significant</font> <font color="blue">market <font color="blue">acceptance</font></font>, we will not have enough     revenues to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition</font>, and if we are unable to compete <font color="blue">effective</font>ly,     the demand for our products, if any, may be reduced</td>
    </tr>
    <tr>
      <td>The  <font color="blue">bio<font color="blue">technology</font></font>  and <font color="blue">pharmaceutical</font> industries are highly     <font color="blue">competitive</font> and subject to rapid and substantial <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>We     face, and <font color="blue">will continue</font> to face, competition in the licensing of desirable     disease  targets,  licensing of desirable <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font>, and     <font color="blue">development</font>  and  marketing  of  our  product <font color="blue">candidates</font> from academic     <font color="blue">institutions</font>, <font color="blue">government</font> agencies, research <font color="blue">institutions</font> and <font color="blue">bio<font color="blue">technology</font></font>     and <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>may also arise from, among other     things:                                         25                                           •                        other drug <font color="blue">development</font> <font color="blue">technologies</font>;                                                 •       methods of preventing or reducing the incidence of disease, including                                 vaccines; and                                                 •             new small molecule or other classes of <font color="blue">therapeutic agents</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developments  </font><font color="blue">by others may</font> render our product <font color="blue">candidates</font> or     <font color="blue">technologies</font> obsolete or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We and our licensees are performing research on or developing     products for the treatment of <font color="blue">several disorders</font> including T-cell mediated     disorders (T-cell cancers, psoriasis, transplant rejection, and rheumatoid     arthritis), oncology, influenza, <font color="blue">hepatitis</font> C and <font color="blue">cardiovascular</font> disorders</td>
    </tr>
    <tr>
      <td>We expect to encounter <font color="blue">significant</font> competition for any of the <font color="blue">pharmaceutical</font>     products we plan to develop</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>that complete <font color="blue"><font color="blue">clinical trial</font>s</font>, obtain     required  <font color="blue">regulatory</font>  approvals and commence <font color="blue">commercial sale</font>s of their     products before their <font color="blue">competitors</font> may achieve a <font color="blue">significant</font> <font color="blue">competitive</font>     advantage</td>
    </tr>
    <tr>
      <td>Such is the case with GSK’s Arranon for T-cell ALL and the     current <font color="blue">neuraminidase</font> inhibitors marketed by <font color="blue">GSK and Roche </font>for influenza</td>
    </tr>
    <tr>
      <td>In     addition, several <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> firms, including major     <font color="blue">pharmaceutical</font>  companies  and specialized structure-based drug design     companies, have announced efforts in the field of structure-based drug     design  and  in  the fields of PNP, <font color="blue">hepatitis</font> C, influenza, and tissue     factor/factor VIIa</td>
    </tr>
    <tr>
      <td>If one or more of our <font color="blue">competitors</font>’ products or programs     are successful, the market for our <font color="blue">products may</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>Compared to us, many of our <font color="blue">competitors</font> and potential <font color="blue">competitors</font>     have <font color="blue">substantially</font> greater:                                           •                                 capital resources;                                                 •       research and <font color="blue">development</font> resources, including personnel and <font color="blue">technology</font>;                                                 •                               <font color="blue">regulatory</font> experience;                                                 •                 preclinical study and <font color="blue">clinical testing</font> experience;                                                 •                    <font color="blue">manufacturing</font> and marketing experience; and                                                 •                               production <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">competitive</font> factors could reduce demand for our     products</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">adequately</font> protect or enforce our <font color="blue">intellectual</font> <font color="blue">property rights</font>     or <font color="blue">secure rights</font> to patents of others, the value of those <font color="blue">rights would</font>     diminish</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability and the <font color="blue">abilities</font>     of our <font color="blue"><font color="blue">collaborator</font>s</font> to obtain <font color="blue">patent protection</font> for our products, methods,     processes and other <font color="blue">technologies</font> we may license or develop, to preserve our     <font color="blue">trade secrets</font>, and to operate <font color="blue">without infringing</font> the <font color="blue">proprietary</font> rights of     third  parties  both  <font color="blue">domestically</font>  and abroad</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of     <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> companies</font> is <font color="blue"><font color="blue">generally</font> <font color="blue">highly uncertain</font></font>,     <font color="blue">involves complex legal</font> and factual questions and has <font color="blue">recently been</font> the     subject of much <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Neither the <font color="blue">United States </font>Patent and Trademark     Office (“USPTO”), nor the courts have a <font color="blue">consistent policy</font> regarding the     breadth of claims allowed or the degree of <font color="blue">protection afforded under</font> many     <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> patents</td>
    </tr>
    <tr>
      <td>The validity, enforceability and     <font color="blue">commercial value</font> of these rights, therefore, is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on avoiding the <font color="blue">infringement</font> of other     parties’ patents and <font color="blue">proprietary</font> rights as well as avoiding the breach of     any licenses relating to our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>In the US, patent     <font color="blue">application</font>s filed in <font color="blue">recent years</font> are <font color="blue">confidential</font> for 18 months, while     older <font color="blue">application</font>s are not <font color="blue">published until</font> the <font color="blue">patent issues</font></td>
    </tr>
    <tr>
      <td>As a result,     avoiding patent <font color="blue">infringement</font> may be <font color="blue">difficult</font> and we may <font color="blue">inadvertently</font>     infringe third-party patents or <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>These <font color="blue">third parties</font>     <font color="blue">could bring</font> claims <font color="blue">against us</font>, our <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">licensors</font> that even     if                                         26       resolved in our favor, could cause us to incur substantial expenses and, if     resolved <font color="blue">against us</font>, could <font color="blue">additional</font>ly cause us to pay substantial damages</td>
    </tr>
    <tr>
      <td>Further,  if  a  patent <font color="blue">infringement</font> suit were brought <font color="blue">against us</font>, our     <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">licensors</font>, we or they could be forced to stop or delay     research, <font color="blue">development</font>, <font color="blue">manufacturing</font> or sales of any <font color="blue">infringing product</font> in     the country or <font color="blue">countries <font color="blue">covered by</font></font> the patent we infringe, unless we can     obtain a <font color="blue">license from</font> the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>Such a license may not be available     on  acceptable  terms,  or  at all, <font color="blue">particularly</font> if the third party is     developing or marketing a product <font color="blue">competitive</font> with the <font color="blue">infringing product</font></td>
    </tr>
    <tr>
      <td>Even  if  we, our <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">licensors</font> were able to obtain a     license, the <font color="blue">rights may</font> be nonexclusive, <font color="blue">which would</font> give our <font color="blue">competitors</font>     access to the same <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>If we or our partners are unable to <font color="blue">adequately</font> protect or enforce     our <font color="blue">intellectual</font> <font color="blue">property rights</font> for our products, methods, processes and     other <font color="blue">technologies</font>, the value of the <font color="blue"><font color="blue">drug product</font> <font color="blue">candidates</font></font> that we license     to <font color="blue">derive revenue would diminish</font></td>
    </tr>
    <tr>
      <td>Additionally, if our products, methods,     processes and other <font color="blue">technologies</font> infringe the <font color="blue">proprietary</font> rights of other     parties, we <font color="blue">could incur</font> substantial costs</td>
    </tr>
    <tr>
      <td><font color="blue">The USPTO </font>has issued to us a     number of US patents for our <font color="blue">various <font color="blue">inventions</font></font> and we have in-licensed     several patents from various <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>We have filed <font color="blue">additional</font> patent     <font color="blue">application</font>s and provisional patent <font color="blue">application</font>s with the USPTO We have     filed a number of corresponding foreign patent <font color="blue">application</font>s and intend to     file <font color="blue">additional</font> foreign and US patent <font color="blue">application</font>s, as appropriate</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you as to:                                           •         the degree and range of protection any patents will afford against                       <font color="blue">competitors</font> with similar products;                                                 •                         if and when <font color="blue">patents will issue</font>; or                                                 •     whether or not <font color="blue">others will</font> obtain patents claiming aspects similar to those                      <font color="blue">covered by</font> our patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">If the USPTO </font><font color="blue">upholds patents issued</font> to others or if the <font color="blue">USPTO          </font>grants patent <font color="blue">application</font>s filed by others, we may have to:                                                 •    obtain licenses or redesign our products or processes to avoid <font color="blue">infringement</font>;                                                 •             stop using the subject matter claimed in those patents; or                                                 •                                    pay damages</td>
    </tr>
    <tr>
      <td>We <font color="blue">may initiate</font>, or others may bring <font color="blue">against us</font>, <font color="blue">litigation</font> or     <font color="blue">administrative</font>  proceedings  related  to <font color="blue">intellectual</font> <font color="blue">property rights</font>,     including proceedings before the USPTO Any <font color="blue">judgment adverse</font> to us in any     <font color="blue">litigation</font> or other proceeding arising in <font color="blue">connection with</font> a patent or patent     <font color="blue">application</font> could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the costs of any such     <font color="blue">proceeding may</font> be substantial whether or not we are successful</td>
    </tr>
    <tr>
      <td>Our success is also <font color="blue">dependent upon</font> the skills, knowledge and     experience, none of which is patentable, of our scientific and technical     personnel</td>
    </tr>
    <tr>
      <td>To  help  protect  our  rights,  we require all employees,     <font color="blue">consultants</font>,  advisors and <font color="blue"><font color="blue">collaborator</font>s</font> to <font color="blue">enter into</font> <font color="blue">confidential</font>ity     <font color="blue">agreements</font> that prohibit the <font color="blue">disclosure</font> of <font color="blue">confidential</font> information to     <font color="blue">anyone outside</font> of our company and require <font color="blue">disclosure</font> and <font color="blue">assignment</font> to us of     their ideas, <font color="blue">development</font>s, discoveries and <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> may     not <font color="blue">provide adequate protection</font> for our <font color="blue">trade secrets</font>, know-how or other     <font color="blue">proprietary</font> information in the event of any <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font>     or the lawful <font color="blue">development</font> by others of such information, and if any of our     <font color="blue">proprietary</font> information is disclosed, our business will suffer because our     <font color="blue">revenues depend upon</font> our ability to license our <font color="blue">technology</font> and any such     events would <font color="blue">significant</font>ly impair the value of such a license</td>
    </tr>
    <tr>
      <td>If we fail to retain our <font color="blue">existing <font color="blue">key personnel</font></font> or fail to attract and     retain  <font color="blue">additional</font>  <font color="blue">key personnel</font>, the <font color="blue">development</font> of our <font color="blue">drug product</font>     <font color="blue">candidates</font> and the expansion of our business will be delayed or stopped</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent upon</font> our senior <font color="blue">management</font> and scientific     team,  the  loss of <font color="blue">whose services might impede</font> the <font color="blue">achievement</font> of our     <font color="blue">development</font> and <font color="blue">commercial objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for <font color="blue">key personnel</font> with     the experience that we require is intense and is expected to continue to     increase</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to attract and retain the required number of skilled     and experienced <font color="blue">management</font>, operational and scientific personnel, will harm     our  business  because  we rely upon these personnel for many critical     functions of our business</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">rely on members</font> of our scientific     advisory                                         27       board  and  <font color="blue">consultants</font>  to  <font color="blue">assist us</font> in <font color="blue">formulating</font> our research and     <font color="blue">development</font> strategy</td>
    </tr>
    <tr>
      <td>All of the members of the <font color="blue">scientific advisory board</font>     and all of our <font color="blue">consultants</font> are otherwise employed and each such member or     <font color="blue">consultant may</font> have <font color="blue">commitments</font> to other entities that may limit their     <font color="blue">availability</font> to us</td>
    </tr>
    <tr>
      <td>If users of our <font color="blue"><font color="blue">drug product</font>s</font> are not reimbursed for use, future sales of     our <font color="blue"><font color="blue">drug product</font>s</font> will decline</td>
    </tr>
    <tr>
      <td>The lack of <font color="blue">reimbursement</font> for the use of our product <font color="blue">candidates</font> by     hospitals, clinics, patients or <font color="blue">doctors will harm</font> our business</td>
    </tr>
    <tr>
      <td>Medicare,     Medicaid, <font color="blue">health maintenance organizations</font> and other third-party payers may     not authorize or <font color="blue">otherwise budget</font> for the <font color="blue">reimbursement</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font>and third-party payers are <font color="blue">increasingly</font> <font color="blue">challenging</font> the prices     charged  for  medical  products  and  services</td>
    </tr>
    <tr>
      <td>We cannot be sure that     third-party payers would view our product <font color="blue">candidates</font> as cost-<font color="blue">effective</font>, that     <font color="blue">reimbursement</font> will be available to consumers or that <font color="blue">reimbursement</font> will be     sufficient to allow our product <font color="blue">candidates</font> to be <font color="blue">marketed on</font> a <font color="blue">competitive</font>     basis</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue"><font color="blue">reimbursement</font> policies</font>, or attempts to contain costs in     the health care industry could limit or restrict <font color="blue">reimbursement</font> for our     product <font color="blue">candidates</font> and would <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business,     because future product sales would decline and we would receive less product     or royalty revenue</td>
    </tr>
    <tr>
      <td><font color="blue">The Medicare </font><font color="blue">prescription drug coverage legislation</font> and <font color="blue">future <font color="blue">legislative</font></font>     or <font color="blue">regulatory</font> reform of the <font color="blue"><font color="blue">healthcare system</font> may affect</font> our ability to sell     our <font color="blue">products profitably</font></td>
    </tr>
    <tr>
      <td>In the United States, there have been a number of <font color="blue">legislative</font> and     <font color="blue">regulatory</font> proposals, at both the federal and state <font color="blue">government</font> levels, to     change the <font color="blue">healthcare system</font> in ways that <font color="blue">could affect</font> our ability to sell     our <font color="blue">products profitably</font>, if approved</td>
    </tr>
    <tr>
      <td>For example, the Medicare Prescription     Drug and Modernization Act of 2003 (“MMA”), went into effect on January 1,     2006  and  has changed the types of drugs <font color="blue">covered by</font> Medicare, and the     <font color="blue">methodology used</font> to determine the price for such drugs</td>
    </tr>
    <tr>
      <td>Further federal and     state proposals and <font color="blue">healthcare reforms</font> are likely</td>
    </tr>
    <tr>
      <td>Our business could be     <font color="blue">harmed by</font> the MMA, by the possible effect of this <font color="blue">legislation on amounts</font>     that <font color="blue">private payors will pay</font> and by other <font color="blue">healthcare reforms</font> that may be     enacted or adopted in the future</td>
    </tr>
    <tr>
      <td>There is a substantial risk of product <font color="blue">liability</font> claims in our business</td>
    </tr>
    <tr>
      <td>If     we are unable to obtain <font color="blue">sufficient insurance</font>, a product <font color="blue">liability</font> claim     <font color="blue">against us</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We face an inherent risk of product <font color="blue">liability</font> exposure related to     the testing of our product <font color="blue">candidates</font> in human <font color="blue"><font color="blue">clinical trial</font>s</font> and will face     even  greater  risks  upon  any <font color="blue">commercialization</font> by us of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have product <font color="blue">liability</font> insurance covering our <font color="blue"><font color="blue">clinical trial</font>s</font>     in the amount of dlra7 million, which we currently believe is adequate to cover     any product <font color="blue">liability</font> exposure we may have</td>
    </tr>
    <tr>
      <td>Clinical trial and product     <font color="blue">liability</font> insurance is becoming <font color="blue">increasingly</font> expensive</td>
    </tr>
    <tr>
      <td>An individual may bring a product <font color="blue">liability</font>     claim <font color="blue">against us</font> if one of our products or product <font color="blue">candidates</font> causes, or is     claimed to have caused, an injury or is found to be unsuitable for consumer     use</td>
    </tr>
    <tr>
      <td>Any product <font color="blue">liability</font> claim brought <font color="blue">against us</font>, with or <font color="blue">without merit</font>,     could result in:                                           •    li<font color="blue">abilities</font> that <font color="blue">substantially</font> exceed our product <font color="blue">liability</font> insurance, which       we would then be required to pay from other sources, if available;                                                 •      an increase of our product <font color="blue">liability</font> insurance rates or the <font color="blue">inability</font> to    maintain <font color="blue">insurance coverage</font> in the future on acceptable terms, or at all;                                                 •                withdrawal of <font color="blue">clinical trial</font> volunteers or patients;                                                 •      damage to our reputation and the reputation of our products, resulting in                                  <font color="blue">lower sales</font>;                                                 •       <font color="blue">regulatory</font> <font color="blue">investigation</font>s that could require <font color="blue">costly recalls</font> or product                                 <font color="blue">modifications</font>;                                                 •                               <font color="blue">litigation</font> costs; and                                                 •        the diversion of <font color="blue">management</font>’s attention from managing our business</td>
    </tr>
    <tr>
      <td>28       If our <font color="blue">computer systems fail</font> or our <font color="blue">facility</font> incurs damage, our business     will suffer</td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">development</font> <font color="blue">activities</font> <font color="blue">depend on</font> the security, integrity     and performance of the <font color="blue">computer systems supporting them</font>, and the failure of     our computer systems <font color="blue">could delay</font> our drug <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>We currently     <font color="blue">store most</font> of our preclinical and <font color="blue">clinical data at</font> our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Duplicate     </font>copies  of <font color="blue">most critical data</font> are stored off-site in a <font color="blue">bank vault</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">significant</font> degradation or failure of our <font color="blue">computer systems could</font> cause us to     <font color="blue">inaccurately</font>  calculate or lose our data</td>
    </tr>
    <tr>
      <td>Loss of data could result in     <font color="blue">significant</font> delays in our drug <font color="blue">development</font> process and any <font color="blue">system failure</font>     <font color="blue">could harm</font> our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">store numerous clinical</font> and <font color="blue">stability samples at</font>     our <font color="blue">facility</font> that could be damaged if our <font color="blue">facility</font> incurred physical damage     or in the event of an <font color="blue">extended power failure</font></td>
    </tr>
    <tr>
      <td>We have backup power systems     in  addition  to  backup  <font color="blue">generators</font> to maintain power to all critical     functions, but any loss of these <font color="blue">samples could</font> result in <font color="blue">significant</font> delays     in our drug <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>If, because of our use of <font color="blue">hazardous materials</font>, we violate any <font color="blue">environmental</font>     controls  or  <font color="blue">regulations</font>  that  apply to <font color="blue">such materials</font>, we may incur     substantial costs and expenses in our <font color="blue">remediation efforts</font></td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> involves the <font color="blue">controlled use</font> of     <font color="blue">hazardous materials</font>, chemicals and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We are     subject to federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing the use,     storage, handling and disposal of these materials and some <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accidental </font><font color="blue">contamination</font> or <font color="blue">injury from</font> these <font color="blue">materials could</font> occur</td>
    </tr>
    <tr>
      <td>In the     event of an <font color="blue">accident</font>, we could be liable for any damages that result and any     li<font color="blue">abilities</font> could exceed our resources</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with <font color="blue">environmental</font> laws     and <font color="blue">regulations</font> could require us to incur substantial <font color="blue">unexpected costs</font>,     <font color="blue">which would</font> <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Common Stock       Our  stock price is likely to be <font color="blue">highly volatile</font> and the value of your     <font color="blue">investment</font> could decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of <font color="blue">bio<font color="blue">technology</font></font> companies in     general have been <font color="blue">highly volatile</font> and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font> in     the future</td>
    </tr>
    <tr>
      <td>Moreover, our stock price has <font color="blue">fluctuated frequently</font>, and these     <font color="blue">fluctuations</font> are often not related to our financial results</td>
    </tr>
    <tr>
      <td>For the twelve     months ended <font color="blue">December </font>31, 2005, the 52-week range of the <font color="blue">market price</font> of our     stock was from dlra3dtta68 to dlra18dtta64 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, in addition     to other <font color="blue">risk factors</font> described in this section, may have a <font color="blue">significant</font>     <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>:                                           •       <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or new products by us or our                                  <font color="blue">competitors</font>;                                                 •         <font color="blue">development</font>s or <font color="blue">disputes concerning patents</font> or <font color="blue">proprietary</font> rights;                                                 •          status of new or <font color="blue">existing licensing</font> or <font color="blue">collaborative</font> <font color="blue">agreements</font>;                                                 •     we or our licensees achieving or failing to achieve <font color="blue">development</font> milestones;                                                 •    publicity regarding actual or <font color="blue">potential medical</font> results relating to products                  under <font color="blue">development</font> by us or our <font color="blue">competitors</font>;                                                 •     publicity regarding <font color="blue">certain public health concerns</font> for which we are or may                           be developing <font color="blue">treatments</font>;                                                 •      <font color="blue">regulatory</font> <font color="blue">development</font>s in both the <font color="blue">United States </font>and foreign countries;                                                 •            public concern as to the safety of <font color="blue">pharmaceutical</font> products;                                                 •            actual or anticipated <font color="blue">fluctuations</font> in our operating results;                                                 •      changes in financial estimates or <font color="blue">recommendations by securities analysts</font>;                                                 •         changes in the structure of <font color="blue">healthcare payment systems</font>, including                   <font color="blue">development</font>s in <font color="blue">price control legislation</font>;                                         29                                           •        <font color="blue">announcements</font> by us or our <font color="blue">competitors</font> of <font color="blue">significant</font> acquisitions,         strategic partnerships, joint ventures or capital <font color="blue">commitments</font>;                                                 •        <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font> or members of our board of                                   <font color="blue">directors</font>;                                                 •        sales of substantial amounts of our stock by <font color="blue">existing <font color="blue">stockholders</font></font>,                        including officers or <font color="blue">directors</font>;                                                 •       economic and other <font color="blue">external factors</font> or other <font color="blue">disasters</font> or crises; and                                                 •              period-to-period <font color="blue">fluctuations</font> in our financial results</td>
    </tr>
    <tr>
      <td>Because <font color="blue">stock ownership</font> is <font color="blue">concentrated</font>, you and other <font color="blue">investors will</font> have     limited influence on stockholder <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our <font color="blue">directors</font>, executive officers and     some  principal  <font color="blue">stockholders</font>  and their <font color="blue">affiliates beneficially</font> owned     <font color="blue">approximately</font>  34dtta1prca  of our outstanding <font color="blue">common stock</font> and <font color="blue">common stock</font>     <font color="blue">equivalents</font></td>
    </tr>
    <tr>
      <td>As a result, these holders, if acting together, are able to     <font color="blue">significant</font>ly influence matters requiring stockholder approval, including     the election of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of ownership may delay, defer     or prevent a change in our control</td>
    </tr>
    <tr>
      <td>We have anti-takeover provisions in our <font color="blue">corporate charter documents</font> that may     result in <font color="blue">outcomes with which</font> you do not agree</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority to issue up to 3cmam178cmam500     shares  of  <font color="blue">undesignated</font>  <font color="blue">preferred stock</font> and to determine the rights,     preferences, privileges and <font color="blue">restrictions</font> of those <font color="blue">shares without further</font>     vote  or  <font color="blue">action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of any     <font color="blue">preferred stock</font> that may be issued in the future may <font color="blue"><font color="blue">adversely</font> affect</font> the     rights of the holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> could     make  it more <font color="blue">difficult</font> for <font color="blue">third parties</font> to acquire a majority of our     <font color="blue">outstanding voting stock</font></td>
    </tr>
    <tr>
      <td>In  addition,  our <font color="blue">certificate</font> of <font color="blue">incorporation provides</font> for     <font color="blue">staggered terms</font> for the members of the board of <font color="blue">directors</font> and <font color="blue">supermajority</font>     approval of the removal of any member of the board of <font color="blue">directors</font> and prevents     our  <font color="blue">stockholders</font> from acting <font color="blue">by written consent</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> also     requires <font color="blue">supermajority</font> approval of any <font color="blue">amendment</font> of these provisions</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions  and  other  provisions  of our by-laws and of <font color="blue">Delaware </font>law     applicable to us <font color="blue">could delay</font> or make more <font color="blue">difficult</font> a merger, tender offer     or <font color="blue">proxy contest involving us</font></td>
    </tr>
    <tr>
      <td>In June 2002, our board of <font color="blue">directors</font> adopted a <font color="blue">stockholder rights</font>     plan  and,  pursuant  thereto,  issued <font color="blue">preferred stock</font> purchase rights     (“Rights”) to the holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Rights </font>have certain     anti-takeover effects</td>
    </tr>
    <tr>
      <td>If triggered, the Rights would cause substantial     dilution to a person or group of persons who acquires more than 15prca (19dtta9prca     for William W Featheringill, a Director who owned <font color="blue">approximately</font> 9dtta95prca as of     <font color="blue">December </font>31, 2005, but owned more than 15prca at the time the Rights were put     in  place)  of  our <font color="blue">common stock</font> on terms not <font color="blue">approved by</font> the board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid dividends on</font> our <font color="blue">common stock</font> and do not anticipate doing     so in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid cash dividends on</font> our stock</td>
    </tr>
    <tr>
      <td>We currently     intend to retain all <font color="blue">future earnings</font>, if any, for use in the operation of     our business</td>
    </tr>
    <tr>
      <td>Accordingly, we do not anticipate <font color="blue">paying cash dividends on</font> our     <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Information Regarding Forward-Looking <font color="blue">Statements  </font>               This discussion contains forward-looking statements, which are     subject to risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These forward-looking statements can     <font color="blue">generally</font>  be  identified  by  the use of words such as “may,” “will,”     “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,”     “predicts,” “potential,” the negative of these words or similar <font color="blue">expressions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Statements  </font>that  describe  our  future plans, strategies, intentions,     <font color="blue">expectations</font>,  objectives, goals or prospects are also forward-looking     statements</td>
    </tr>
    <tr>
      <td><font color="blue">Discussions </font>containing these forward-looking statements are     <font color="blue">principally</font>  contained  in “Business” and “Management’s Discussion and     Analysis of Financial Condition and Results of Operations”, as well as any     <font color="blue">amendment</font>s  we  make to those sections in <font color="blue">filings with</font> the SEC  <font color="blue">These     </font>forward-looking statements include, but are not limited to, statements     about:                                         30                                           •    the <font color="blue">initiation</font>, timing, progress and results of our preclinical and clinical                   trials, research and <font color="blue">development</font> programs;                                                 •    the <font color="blue">further preclinical</font> or clinical <font color="blue">development</font> and <font color="blue">commercialization</font> of our                              product <font color="blue">candidates</font>;                                                 •     the <font color="blue">implementation</font> of our business model, strategic plans for our business,                       product <font color="blue">candidates</font> and <font color="blue">technology</font>;                                                 •     our ability to establish and maintain <font color="blue">collaboration</font>s with <font color="blue">bio<font color="blue">technology</font></font> or   <font color="blue"><font color="blue">pharmaceutical</font> companies</font> and <font color="blue"><font color="blue">government</font>al agencies</font> or other <font color="blue">third parties</font>;                                                 •         the scope of protection we are able to establish and maintain for  <font color="blue">intellectual</font> <font color="blue">property rights</font> covering our product <font color="blue">candidates</font> and <font color="blue">technology</font>;                                                 •       our ability to operate our business <font color="blue">without infringing</font> the <font color="blue">intellectual</font>                           <font color="blue">property rights</font> of others;                                                 •      estimates of our expenses, future revenues, capital <font color="blue">requirements</font> and our                        needs for <font color="blue"><font color="blue">additional</font> financing</font>;                                                 •           the timing or likelihood of <font color="blue">regulatory</font> filings and approvals;                                                 •          our <font color="blue">negotiations with</font> the FDA for a <font color="blue">special protocol assessment</font>;                                                 •                           our <font color="blue">financial performance</font>; and                                                 •               <font color="blue">competitive</font> companies, <font color="blue">technologies</font> and our industry</td>
    </tr>
    <tr>
      <td>These <font color="blue">statements reflect</font> our current views <font color="blue">with respect</font> to future     events and are <font color="blue">based on assumptions</font> and subject to risks and <font color="blue">uncertainties</font>     which  may cause our actual results, performance or <font color="blue">achievement</font>s to be     <font color="blue">materially</font> different from any future results, <font color="blue">performances</font> or <font color="blue">achievement</font>s     expressed  or  implied  by the forward-looking statements</td>
    </tr>
    <tr>
      <td>Given these     <font color="blue">uncertainties</font>, you should not place <font color="blue">undue reliance on</font> these forward-looking     statements</td>
    </tr>
    <tr>
      <td>” Also, these forward-looking statements represent our estimates and     <font color="blue">assumptions only as</font> of the date of this document</td>
    </tr>
    <tr>
      <td>You  should  read  this  discussion  <font color="blue">completely</font> and with the     understanding that our <font color="blue">actual future</font> results may be <font color="blue">materially</font> different     from what we expect</td>
    </tr>
    <tr>
      <td>We may not update these forward-looking statements,     <font color="blue">even though</font> our situation may change in the future</td>
    </tr>
    <tr>
      <td>We qualify all of our     forward-looking statements by these <font color="blue">cautionary statements</font></td>
    </tr>
  </tbody>
</table>